A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer

European Urology

Volumn 67, Issue 4, 2015, Pages 673-679

  Venkitaraman, Ramachandran ^a   Lorente, David ^b   Murthy, Vedang ^c   Thomas, Karen ^d   Parker, Lydia ^b   Ahiabor, Ruth ^b   Dearnaley, David ^b   Huddart, Robert ^b   De Bono, Johann ^b   Parker, Chris ^d  

^a UNIVERSITY OF SUFFOLK   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c TATA MEMORIAL HOSPITAL   (India)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Dexamethasone; Prednisolone; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ANALGESIC AGENT; DEXAMETHASONE; GLUCOSE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; GLUCOCORTICOID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALGESIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GLUCOSE BLOOD LEVEL; HEMATOLOGIC DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; WEIGHT GAIN; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TIME; TREATMENT OUTCOME;

AGED; DEXAMETHASONE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923108661     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.10.004     Document Type: Article

References (31)

1. H.M. Khandwala, R. Vassilopoulou-Sellin, C.J. Logethetis, and K.E. Friend Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer Endocr Pract 7 2001 11 15
2. I. Tannock, M. Gospodarowicz, W. Meakin, T. Panzarella, L. Stewart, and W. Rider Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 1989 590 597
3. S.D. Fosså, P.H. Slee, and M. Brausi Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group J Clin Oncol 19 2001 62 71
4. R. Venkitaraman, K. Thomas, R.A. Huddart, A. Horwich, D.P. Dearnaley, and C.C. Parker Efficacy of low-dose dexamethasone in castration-refractory prostate cancer BJU Int 101 2008 440 443
5. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
6. J.S. De Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
7. C.N. Sternberg, P. Whelan, and J. Hetherington Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer Oncology 68 2005 2 9
8. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
9. W. Berry, S. Dakhil, M. Modiano, M. Gregurich, and L. Asmar Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer J Urol 168 2002 2439 2443
10. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
11. K. Nishimura, N. Nonomura, and Y. Yasunaga Low doses of oral dexamethasone for hormone-refractory prostate carcinoma Cancer 89 2000 2570 2576
12. J. Shamash, T. Powles, and S.J. Sarker A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred diethylstilbestrol Br J Cancer 104 2011 620 628
13. S.D. Fosså, A.-B. Jacobsen, and C. Ginman Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study Eur Urol 52 2007 1691 1699
14. O. Sartor, M. Weinberger, A. Moore, A. Li, and W.D. Figg Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer Urology 52 1998 252 256
15. J.A. Storlie, J.C. Buckner, G.A. Wiseman, P.A. Burch, L.C. Hartmann, and R.L. Richardson Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma Cancer 76 1995 96 100
16. M. Morioka, T. Kobayashi, and Y. Furukawa Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone Urol Int 68 2002 10 15
17. T. Saika, N. Kusaka, and T. Tsushima Okayama Urological Cancer Collaborating Group. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients Int J Urol 8 2001 290 294
18. G. Attard, A.H.M. Reid, and J.S. de Bono Abiraterone acetate is well tolerated without concomitant use of corticosteroids J Clin Oncol 28 2010 e560 e561 author reply e562
19. D. Lorente, K. Weatherstone, and A. Omlin Tumor responses after steroid switch of prednisolone (P) to dexamethasone (D) in castration-resistant prostate cancer (CRPC) patients (pts) on abiraterone acetate (AA) [abstract 2918] Eur J Cancer 2013 49
20. A.L. Weitzman, G. Shelton, and N. Zuech Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer J Urol 163 2000 834 837
21. T.B. Dorff, and E.D. Crawford Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer Ann Oncol 24 2013 31 38
22. A. Eichholz, R. Ferraldeschi, G. Attard, and J.S. de Bono Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer Mol Cell Endocrinol 360 2012 68 75
23. A. Yano, Y. Fujii, A. Iwai, Y. Kageyama, and K. Kihara Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells Clin Cancer Res 12 2006 3003 3009
24. K. Nishimura, N. Nonomura, and E. Satoh Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer J Natl Cancer Inst 93 2001 1739 1746
25. R.B. Montgomery, T.S. Kheoh, and A. Molina Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D) [abstract 5014] J Clin Oncol 31 Suppl 2013
26. H.I. Scher, K. Fizazi, and F. Saad Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor [abstract 6] J Clin Oncol 31 Suppl 2013
27. X.Y. Zhao, P.J. Malloy, and A.V. Krishnan Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 2000 703 706
28. J. Richards, A.C. Lim, and C.W. Hay Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 2012 2176 2182
29. B. Sahu, M. Laakso, and P. Pihlajamaa FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells Cancer Res 73 2013 1570 1580
30. V.K. Arora, E. Schenkein, and R. Murali Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Cell 155 2013 1309 1322
31. E.J. Small, S. Halabi, and N.A. Dawson Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 22 2004 1025 1033